Current therapy and drug resistance in metastatic castration-resistant prostate cancer

Drug Resist Updat. 2023 May:68:100962. doi: 10.1016/j.drup.2023.100962. Epub 2023 Apr 14.

Abstract

Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of cancer-related death among men in the world. In addition, it is very difficult for clinical treatment because of the natural or acquired drug resistance of CRPC. Mechanisms of drug resistance are extremely complicated and how to overcome it remains an urgent clinical problem to be solved. Thus, a comprehensive and thorough understanding for mechanisms of drug resistance in mCRPC is indispensable to develop novel and better therapeutic strategies. In this review, we aim to review new insight of the treatment of mCRPC and elucidate mechanisms governing resistance to new drugs: taxanes, androgen receptor signaling inhibitors (ARSIs) and poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). Most importantly, in order to improve efficacy of these drugs, strategies of overcoming drug resistance are also discussed based on their mechanisms respectively.

Keywords: Androgen receptor signaling inhibitors (ARSIs); Chemotherapy; Drug resistance; Metastatic castration-resistance prostate cancer (mCRPC); Poly (ADP‐ribose) polymerase (PARP) inhibitors (PARPi).

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Resistance, Neoplasm
  • Humans
  • Male
  • Prostatic Neoplasms, Castration-Resistant* / drug therapy
  • Prostatic Neoplasms, Castration-Resistant* / genetics
  • Prostatic Neoplasms, Castration-Resistant* / pathology
  • Signal Transduction
  • Taxoids

Substances

  • Taxoids